cerebral small vessel disease-cognitive impairment
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Inclusion criteria were (1) age between 40 and 75 years; (2) patient or caregiver reports of cognitive decline in memory or other cognitive domains lasting at least 3 months; (3) criteria of the Diagnostic and Statistical Manual of Mental Disorders, fourth edition, with normal or mildly impaired activities of daily living, and mental state examination (MMSE) score =20(primary) or =24(junior high or above) , Montreal cognitive assessment (MOCA-RRB- score =26; (4) the criteria for neuroimaging to report vascular changes on MRI were: 1 multiple (=3) small supratentorial infarcts (3-15 mm in diameter) with or without any degree of white matter degeneration; Or moderate to severe white matter degeneration (Fazekas score =2) with/without small infarcts, or one or more small subcortical infarcts located in the caudate nucleus, globus pallidus, or thalamus; 2 no cortical and watershed infarction, hemorrhage, hydrocephalus and specific cause, 3 no atrophy of hippocampus or entorhinal cortex.
Exclusion criteria
Exclusion criteria: The exclusion criteria were: (1) history of intracranial hemorrhage or massive hemorrhage in other parts of the body, (2) history of atrial fibrillation or myocardial infarction within 6 months, (3) hereditary or inflammatory small vessel disease, (4) severe hemorrhagic disease, (3) history of acute myocardial infarction, (3) history of acute myocardial infarction, (3) history of acute myocardial infarction, (4) history of acute myocardial infarction, (3) history of acute myocardial infarction, (3) history of acute myocardial infarction, (4) history of acute myocardial infarction, (3) history of acute myocardial infarction, (4) history of acute myocardial infarction (5) history of brain tumor, psychosis or acute stroke within 6 months after symptom onset; (6) severe kidney or liver disease, cancer or severe disease; (7) systolic blood pressure < GT; 200 mmhg; (8) taking anti-dementia drugs within 1 month; (9) without informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| White matter lesion volume of MRI; | — |
Secondary
| Measure | Time frame |
|---|---|
| Trail Making Test A and B;Auditory Verbal Learning Test;Boston Naming Test;Differential expression of micRNA in serum exosomes;Montreal Cognitive Assessment; | — |
Countries
China
Contacts
Beijing Hospital of Traditional Chinese medicine